Variability in telavancin cross-reactivity among vancomycin immunoassays.
نویسندگان
چکیده
Telavancin is a semisynthetic lipoglycopeptide with a dual mechanism of action against Gram-positive pathogens. Two brief reports have suggested potential cross-reactivity of telavancin with the vancomycin particle-enhanced turbidometric immunoassay (PETIA). The purpose of this study was to evaluate several commercially available vancomycin immunoassays (fluorescence polarization [FPIA], enzyme-multiplied immunoassays [EMIT], PETIA, and chemiluminescent immunoassay [CMIA]) for cross-reactivity with telavancin. Seven sites were selected to analyze serum samples for vancomycin. Each site received a set of samples (n = 18) which combined drug-free serum with telavancin, 7-OH telavancin metabolite, or vancomycin. Immunoassays demonstrating potential cross-reactivity were further evaluated by sending a duplicate sample set to multiple laboratories. Cross-reactivity was defined as the percent theoretical concentration (reported concentration/theoretical concentration × 100). No cross-reactivity was seen with FPIA or EMIT. Within the theoretical concentration range of 5 to 120 μg/ml of telavancin, the Synchron PETIA system reported vancomycin concentrations ranging from 4.7 to 54.2 μg/ml compared to vancomycin concentrations from 1.1 to 5.6 μg/ml for the Vista PETIA system. The Architect CMIA system reported vancomycin concentrations in the range of 0.27 to 0.97 μg/ml, whereas Advia Centaur XP CMIA reported vancomycin concentrations between 1.6 and 31.6 μg/ml. The Architect CMIA immunoassay had the lowest percent cross-reactivity (0.8 to 5.4%), while the Synchron PETIA immunoassay demonstrated the highest percent cross-reactivity (45.2 to 53.8%). Telavancin samples measured by liquid chromatography-mass spectroscopy were within 93.9 to 122% of theoretical concentrations. Vancomycin concentrations were not measured in any 7-OH telavancin-spiked sample. Vancomycin concentrations measured by liquid chromatography-mass spectroscopy were within 57.2 to 113% of theoretical concentrations. PETIA and CMIA measured vancomycin concentrations in telavancin-spiked samples. Significant variability in percent cross-reactivity was observed for each platform regardless of immunoassay method.
منابع مشابه
Variability in Telavancin Cross - Reactivity 1 Among Vancomycin Immunoassays
24 Telavancin is a semisynthetic lipoglycopeptide with a dual mechanism of action against 25 Gram-positive pathogens. Two brief reports have suggested potential cross-reactivity of 26 telavancin with the vancomycin particle-enhanced turbidometric immunoassay (PETIA). 27 The purpose of this study was to evaluate several commercially available vancomycin 28 immunoassays (fluorescence polarization...
متن کاملEfficacy and Safety of Telavancin in Clinical Trials: A Systematic Review and Meta-Analysis
INTRODUCTION The epidemiology and antibiotic resistance of Staphylococcus aureus have evolved, underscoring the need for novel antibiotics, particularly against methicillin-resistant S. aureus (MRSA). Telavancin is a bactericidal lipoglycopeptide with potent activity against Gram-positive pathogens. OBJECTIVE To systematically review and synthesize the available evidence from randomized contr...
متن کاملTelavancin, a new lipoglycopeptide antimicrobial, in complicated skin and soft tissue infections
Telavancin, a novel lipoglycopeptide with rapid concentration-dependent bactericidal effects, is a semisynthetic derivative of the glycopeptide, vancomycin. Telavancin has a dual mechanism of action, ie, inhibition of peptidoglycan polymerization and disruption of the bacterial membrane. It has linear pharmacokinetics, rapid bactericidal killing, and broad spectrum activity against Gram positiv...
متن کاملEfficacy of telavancin in patients with specific types of complicated skin and skin structure infections.
BACKGROUND Telavancin is approved in the USA and Canada for the treatment of Gram-positive complicated skin and skin structure infections (cSSSIs) based on the results of the Phase 3 Assessment of TeLAvancin in complicated Skin and skin structure infections (ATLAS) trials, which demonstrated non-inferiority of telavancin to vancomycin. METHODS We conducted a post hoc analysis of the ATLAS stu...
متن کاملTelavancin (vibativ), a new option for the treatment of gram-positive infections.
INTRODUCTION In recent years, the development of bacterial resistance has escalated, especially among gram-positive microorganisms. Pathogens identified as Staphylococcus species (spp.) and Enterococci spp. have become extremely challenging to eradicate, par ticularly vancomycinresistant strains. Vancomycin (Vancocin, ViroPharma) has been the mainstay for treating gram-positive infections for d...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Antimicrobial agents and chemotherapy
دوره 58 12 شماره
صفحات -
تاریخ انتشار 2014